Every 5 seconds worldwide, one person dies from sepsis. With a mortality rate of 25% to 60%, sepsis is already life-threatening. Yet more dangerous than primary sepsis is the hidden "secondary crisis" during its course: sepsis-associated secondary infection. Mostly caused by impaired immunity and pathogen invasion, this type of infection can raise mortality by over 30% once it occurs, posing a major challenge in clinical care.

Etiology and Clinical Characteristics of Sepsis

Sepsis is caused by infection. After pathogens invade the body, they trigger an uncontrolled "systemic inflammatory storm", which ultimately leads to multiple organ failure.

The elderly, patients with diabetes, and those who have undergone surgery or trauma are all high-risk groups for sepsis. Among them, burn patients are at extremely high risk due to damaged skin barriers and highly susceptible wound infections. Sepsis after burns progresses more rapidly and has a significantly higher mortality rate, making it one of the leading causes of death in burn patients.

Clinical data show that approximately 60% of sepsis cases are associated with infections of the lungs, abdominal cavity and skin wounds, with burn wound infections being a particularly critical risk factor.

Innovative Immunotherapies: Tackling Inflammatory Imbalance

The core challenge in sepsis treatment lies in "suppressing excessive inflammation without compromising the body's antibacterial capacity." Traditional drugs cannot achieve such precise balance, but the emergence of targeted immunotherapies is breaking this deadlock, with impressive achievements both in China and globally.

In China, STC3141, an innovative drug independently developed by Grand Pharmaceutical, has achieved a major breakthrough in its Phase II clinical trial, becoming the first targeted drug proven effective for sepsis patients. It can precisely neutralize harmful substances causing tissue damage and reverse organ injury from excessive immune responses. Seven days after treatment, the high-dose group showed significantly better improvement in organ dysfunction scores than the placebo group, with favorable safety profiles.

Its mechanism of action has been published in two top journals, Nature Communications and Critical Care. STC3141 is expected to fill the global gap in targeted sepsis therapy, with plans to apply for breakthrough therapy designation in subsequent development.

Source：Critical Care

Good news has also emerged in basic scientific research.A peptide drug, SK56, developed by a team from Kunming Yan’an Hospital, has been published in Nature Immunology.This drug precisely targets the key site of uncontrolled inflammation, inhibiting the spread of inflammatory factors without compromising the body’s natural antibacterial ability.Even when the optimal treatment window is missed and administration is delayed by 4 to 16 hours, it can significantly improve the survival rate of septic mice, offering hope for critically ill patients.

A team from China Pharmaceutical University has taken a different approach, starting from natural products.They confirmed that sinomenine can repair metabolic disorders caused by sepsis, providing a scientific basis for the use of natural medicines in the treatment of sepsis.

Internationally, immunomodulatory therapy is also a hot research area.A number of targeted monoclonal antibody drugs have entered clinical stages, focusing on core targets of the inflammatory response, aiming to reduce organ damage by blocking the spread of inflammation, thus providing more options for sepsis treatment.

Source：Nature Immunology

Precision Nanodelivery for Antibacterial & Immune Repair

Traditional drugs often face the problem of "failure to reach the lesion and reduced efficacy". However, innovations in nanocarrier technology have enabled drugs to achieve the dual upgrade of "precision delivery + efficient efficacy", opening up a new path for sepsis treatment.

Among them, the development of the Bacteria-Targeted Deformable Macrophage Nanoactivator (BATMAN) has shown amazing potential. Developed jointly by the team led by Professor Luo Yang, Vice Dean of the School of Medicine, Chongqing University, and the team led by Liang Xingjie from the National Center for Nanoscience and Technology, the results were published in Science Translational Medicine on December 24, 2025.

After entering the body, this nanoactivator can accurately "find" the site of lung infection and attach to the surface of bacteria. It deforms and reorganizes under the action of bacteria, releasing substances that enhance the phagocytic capacity of immune cells — it can not only efficiently eliminate pathogens, but also repair the damaged immune system, perfectly solving the core dilemma of sepsis: "difficult to control infection and difficult to repair immunity".

In animal experiments, it significantly improved the survival rate of sepsis caused by multiple pathogenic bacteria compared with traditional antibiotic therapy, laying a solid foundation for subsequent clinical transformation.

ZVAST BIO has established mature animal models of sepsis (including burn-induced sepsis).

Welcome to contact us for inquiries.

Source：Science Translational Medicine

These technologies abandon the broad-spectrum, "non-selective" approach of traditional antibiotics, achieving the synergy of precise targeting and immune regulation, resulting in improved efficacy and reduced side effects.

For wound infections in post-burn sepsis, a number of dedicated technologies have emerged.The nanozyme spray developed by Professor Qian Yu’s team at Zhejiang Provincial Hospital of Traditional Chinese Medicine can eliminate over 99% of drug-resistant bacteria via photothermal action within 3 minutes, and achieve a 95% wound healing rate in 14 days. The findings were published in Advanced Functional Materials.

The 3D micro-nano etched dressing developed by Tongji Hospital increases drug loading by 61 times, reduces the risk of infection-induced sepsis, and accelerates wound healing by 43%.

Source：Advanced Functional Materials

Challenges and Outlook: From Laboratory to Clinic

For critical care physicians and pharmaceutical R&D personnel, innovation in the field of sepsis is both a challenge and an opportunity. Currently, this field still faces many difficulties: low clinical translation efficiency of immunotherapeutic drugs, unclear mechanisms of multi-target synergistic therapy, and lack of "biomarkers" for accurate diagnosis.

High-quality preclinical research is the key to breaking through these bottlenecks. The maturity of technologies such as nanocarriers is making the transformation path between basic research and clinical application increasingly smooth.

References

1. Bellomo R, Patava J, Van Lancker R, et al. A dose-adjusted, open-label, pilot study of the safety, tolerability, and pharmacokinetics of STC3141 in critically ill patients with sepsis. Pharmacol Res Perspect. 2024;12(5):e70015. doi:10.1002/prp2.70015

2. Sun J, Yang J, Tao J, et al. Delaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response. Nat Immunol. 2025;26(10):1660-1672. doi:10.1038/s41590-025-02280-x

Sepsis Animal Model

Modeling: Experimental mice were administered 10 mg/kg LPS by intraperitoneal injection, while the blank control group received an equal volume of normal saline intraperitoneally.